🇺🇸 FDA
Pipeline program

Aritinercept

AUR-200-2024-02

Phase 2 small_molecule active

Quick answer

Aritinercept for Myasthenia Gravis, Generalized is a Phase 2 program (small_molecule) at Aurinia Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Aurinia Pharmaceuticals
Indication
Myasthenia Gravis, Generalized
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials